Contineum Therapeutics (CTNM) Interest Expenses (2023)

Contineum Therapeutics (CTNM) recorded quarterly Interest Expenses of $116000.0 in Q2 2023, up 26.09% quarter-over-quarter from $92000.0 in Q1 2023.

Contineum Therapeutics (CTNM) Interest Expenses (2023) Analysis & Trends

Contineum Therapeutics' Interest Expenses history runs 1 years deep, the most recent figure standing at $116000.0 for Q2 2023.

In Q2 2023, Interest Expenses changed N/A year-over-year to $116000.0; the TTM figure through Mar 2024 stood at $116000.0 (changed N/A YoY), while the FY2023 annual figure was $208000.0, changed N/A from the prior year.
Interest Expenses was $116000.0 for Q2 2023 at Contineum Therapeutics, up from $92000.0 in the prior quarter.
In the past five years, Interest Expenses ranged from a high of $116000.0 in Q2 2023 to a low of $92000.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Expense (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-5.50 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	61,000.00
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-332,000.00
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-2,753.00
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-5.58 Mn
10	Contineum Therapeutics	423.05 Mn	423.05 Mn	-	-

Download Data